Albany, US) DelveInsight launched a new report on “Alport Syndrome Market Insights, Epidemiology and Market Forecast-2030”.
DelveInsight’s “Alport Syndrome – Market Insights, Epidemiology and Market Forecast 2030″ report delivers an in-depth understanding of the Alport Syndrome, historical and forecasted epidemiology as well as the Alport Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the facts of the report
1. Alport syndrome occurs in approximately 1 in 50,000 newborns.
2. Alport syndrome is estimated to account for 3% of children with chronic kidney disease and 0.2% of adults with end-stage renal disease in the United States.
3. Alport Syndrome is estimated to affect approximately 1 in 5,000-10,000 people in the general population in the United States.
Key benefits of the report
1. Alport Syndrome market report covers a descriptive overview and comprehensive insight of the Alport Syndrome epidemiology and Alport Syndrome market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Alport Syndrome market report provides insights on the current and emerging therapies.
3. Alport Syndrome market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Alport Syndrome market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Alport Syndrome market.
Request for sample pages : https://www.delveinsight.com/sample-request/alport-syndrome-market
“According to DelveInsight, Alport syndrome primarily affects men.”
Alport Syndrome (also referred to as hereditary nephritis) is an inherited progressive form of glomerular disease that is often associated with sensorineural hearing loss and ocular abnormalities. Patients with Alport Syndrome will experience progressive loss of kidney function. Almost all patients experience blood in their urine (hematuria) as well as proteinuria at symptom onset. The kidneys lose function as this condition progresses, resulting in kidney failure. There are three genetic Sub-divisions. X-linked Alport Syndrome (XLAS) is the most common; in these families affected males typically have more severe disease than affected females.
In autosomal recessive Alport Syndrome (ARAS) the severity of disease in affected males and females is similar. There is also an autosomal dominant form (ADAS) that affects males and females with equal severity. Alport Syndrome is caused by mutations in specific genes.
People with Alport Syndrome frequently develop sensor neural hearing loss, which is caused by abnormalities of the inner ear, during late childhood or early adolescence. Affected individuals may also have misshapen lenses in the eyes (anterior lenticonus) and abnormal coloration of the light- sensitive tissue at the back of the eye (retina). These eye abnormalities seldom lead to vision loss.
“According to DelveInsight, Significant hearing loss, eye abnormalities, and progressive kidney disease are more common in males with Alport Syndrome than in affected females. “
The launch of the emerging therapies is expected to significantly impact Alport Syndrome treatment scenario in the upcoming years:-
Drugs covered
1. Roxadustat
And many others
The key players in Alport Syndrome market are:
1. FibroGen
And many others
Request for sample pages : https://www.delveinsight.com/sample-request/alport-syndrome-market
Table of contents
1. Report Introduction
2. Alport Syndrome Market Overview at a Glance
2.1. 7 Major Market Size of Alport Syndrome in 2017
2.2. 7 Major Market Size of Alport Syndrome in 2030
3. Disease Background and Overview: Alport Syndrome
3.1. Introduction
3.2. Causes
3.3. Symptoms
3.4. Risk Factor
3.5. Pathophysiology
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Assumptions and Caveats
4.2. 7MM Prevalent cases of Alport Syndrome (2017-2030)
4.3. Age-specific prevalence of Alport Syndrome (2017-2030)
4.4. Sex-specific prevalence of Alport Syndrome (2017-2030)
4.5. Type -specific-specific prevalence of Alport Syndrome (2017-2030)
4.6. Diagnosed and Treatable Cases of Alport Syndrome (2017-2030)
4.7. Alport Syndrome: Country- Wise Epidemiology
4.8. United States
4.8.1. Assumptions and Rationale
4.8.2. Prevalent cases of Alport Syndrome in the United States (2017-2030)
4.8.3. Age-specific prevalence of Alport Syndrome in the United States (2017-2030)
4.8.4. Sex-specific prevalence of Alport Syndrome in the United States (2017-2030)
4.8.5. Type -specific-specific prevalence of Alport Syndrome in the United States (2017-2030)
4.8.6. Diagnosed and Treatable Cases of Alport Syndrome in the United States (2017-2030)
4.9. EU-5
4.10. Assumptions and Rationale
4.11.Germany
4.11.1. Prevalent cases of Alport Syndrome in Germany (2017-2030)
4.11.2. Age-specific prevalence of Alport Syndrome in Germany (2017-2030)
4.11.3. Sex-specific prevalence of Alport Syndrome in Germany (JIA) (2017-2030)
4.11.4. Type -specific-specific prevalence of Alport Syndrome in Germany (2017-2030)
4.11.5. Diagnosed and Treatable Cases of Alport Syndrome in Germany (2017-2030)
4.12. France
4.12.1. Prevalent cases of Alport Syndrome in France (2017-2030)
4.12.2. Age-specific prevalence of Alport Syndrome in France (2017-2030)
4.12.3. Sex-specific prevalence of Alport Syndrome in France (2017-2030)
4.12.4. Type -specific-specific prevalence of Alport Syndrome in France (2017-2030)
4.12.5. Diagnosed and Treatable Cases of Alport Syndrome in France (2017-2030)
4.13. Italy
4.13.1. Prevalent cases of Alport Syndrome in Italy (2017-2030)
4.13.2. Age-specific prevalence of Alport Syndrome in Italy (2017-2030)
4.13.3. Sex-specific prevalence of Alport Syndrome in Italy (2017-2030)
4.13.4. Type -specific-specific prevalence of Alport Syndrome in Italy (2017-2030)
4.13.5. Diagnosed and Treatable Cases of Alport Syndrome in Italy (2017-2030)
4.14. Spain
4.14.1. Prevalent cases of Alport Syndrome in Spain (2017-2030)
4.14.2. Age-specific prevalence of Alport Syndrome in Spain (2017-2030)
4.14.3. Sex-specific prevalence of Alport Syndrome in Spain (2017-2030)
4.14.4. Type -specific-specific prevalence of Alport Syndrome in Spain (2017-2030)
4.14.5. Diagnosed and Treatable Cases of Alport Syndrome in Spain (2017-2030)
4.15.United Kingdom
4.15.1. Prevalent cases of Alport Syndrome in the United Kingdom (2017-2030)
4.15.2. Age-specific prevalence of Alport Syndrome in the United Kingdom (2017-2030)
4.15.3. Sex-specific prevalence of Alport Syndrome in the United Kingdom (2017-2030)
4.15.4. Type -specific-specific prevalence of Alport Syndrome in the United Kingdom (2017-2030)
4.15.5. Diagnosed and Treatable Cases of Alport Syndrome in the United Kingdom (2017-2030)
4.16.Japan
4.16.1. Prevalent cases of Alport Syndrome in Japan (2017-2030)
4.16.2. Age-specific prevalence of Alport Syndrome in Japan (2017-2030)
4.16.3. Sex-specific prevalence of Alport Syndrome in Japan (2017-2030)
4.16.4. Type -specific-specificprevalence of Alport Syndrome in Japan (2017-2030)
4.16.5. Diagnosed and Treatable Cases of Alport Syndrome in Japan (2017-2030)
5. Treatments & Medical Practices
5.1. Treatment Algorithm
5.2. Treatment Guidelines
List to be continued in the report…
6. Emerging Therapies
7. Key Cross Competition
7.1. Bardoxolone Methyl: Reata Pharmaceuticals
7.1.1. Regulatory Milestones
7.1.2. Clinical Development
7.1.3. Product Profile
7.1.4. Clinical Pipeline Activity
7.1.4.1. Ongoing Trials Information
7.1.4.2. Clinical Trial by Phase
7.2. RG 012/ SAR339375: Regulus Therapeutics/ Sanofi Genzyme
7.2.1. Regulatory Milestones
7.2.2. Clinical Development
7.2.3. Product Profile
7.2.4. Clinical Pipeline Activity
7.2.4.1. Ongoing Trials Information
7.2.4.2. Clinical Trial by Phase
List to be continued in the report…
8. Alport Syndrome Market Size
8.1. Key Findings
8.2. Total 7MM Alport Syndrome Market Analysis
8.3. Overview of Total Alport Syndrome Market
8.4. Market size of Alport Syndrome by 7MM (2017-2030)
9. 7MM Alport Syndrome: Country-Wise Market Analysis
10. United States Market Size
10.1. Total Market Size of Alport Syndrome
10.2. Market Size of Alport Syndrome by Therapies
11. Germany Market Size
11.1. Total Market Size of Alport Syndrome
11.2. Market Size of Alport Syndrome by Therapies
12. France Market Size
12.1. Total Market Size of Alport Syndrome
12.2. Market Size of Alport Syndrome by Therapies
13. United Kingdom Market Size
13.1. Total Market Size of Alport Syndrome
13.2. Market Size of Alport Syndrome by Therapies
14. Spain Market Size
14.1. Total Market Size of Alport Syndrome
14.2. Market Size of Alport Syndrome by Therapies
15. Italy Market Size
15.1. Total Market Size of Alport Syndrome
15.2. Market Size of Alport Syndrome by Therapies
16. Japan Market Size
16.1. Total Market Size of Alport Syndrome
16.2. Market Size of Alport Syndrome by Therapies
17. Report Methodology
17.1. Sources Used
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
Related Reports:
Alport Syndrome – Pipeline Insights, 2020
The Alport Syndrome report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Alport Syndrome across the complete product development cycle, including all clinical and nonclinical stages.
Alport Syndrome – Epidemiology Forecast to 2030
The Alport Syndrome epidemiology covered in the report provides historical as well as forecasted Alport Syndrome epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/